32 C
Vientiane
Friday, May 9, 2025
spot_img
Home Blog Page 563

Interlace at Consensus 2025: Card Solutions Connect Global Web3 Firms in the “Year of Payfi”

SINGAPORE, Feb. 26, 2025 /PRNewswire/ — From February 18 to 20, 2025, Consensus Hong Kong took place at the Hong Kong Convention and Exhibition Centre, attracting global attention from the Web3 and fintech communities in what many are calling the “Year of PayFi” in the crypto industry. During the event, Interlace, a leading fintech infrastructure provider, took the stage at the highly anticipated PayFi Summit 2025. Alongside prominent industry innovators such as the Solana Foundation, Huma Finance, and DePHY, Interlace offered insights into the evolving world of cross-border payments. The summit further explored PayFi’s cutting-edge applications and shed light on emerging industry trends, market opportunities, and the bright prospects ahead.

Interlace CEO Michael Wu
Interlace CEO Michael Wu

PayFi, short for Payment Finance, is an innovative technology and application model that integrates payment systems with financial services within the blockchain and cryptocurrency space. According to Lily Liu, Chair of the Solana Foundation, PayFi leverages blockchain technology to revolutionize payment systems, enabling more efficient, low-cost transactions while creating a new financial experience. Its goal is to develop more complex financial products and applications, building an integrated value chain that fosters the creation of a new financial ecosystem.

Technological innovation in financial services lies at the heart of Interlace’s mission. As a leader in card issuing infrastructure, Interlace delivers efficient, cost-effective, and multi-currency financial solutions that seamlessly bridge Web3 and Web2, connecting modern financial systems with emerging markets. By serving as a key enabler of stablecoin usage in cross-border payments, Interlace supports scalable, efficient financial transactions on a global scale.

Among the services offered are Card as a Service (CaaS), Banking as a Service (BaaS), and Wallet as a Service (WaaS), all of which allow businesses to effortlessly integrate financial capabilities into their existing platforms via APIs. Additionally, Interlace offers essential products like global accounts, acquiring services, and the issuance of both virtual and physical cards.

Michael Wu, CEO of Interlace, further elaborated on the company’s comprehensive “end-to-end” CaaS solution at the summit, which covers the entire process from wallet management to card issuance. Key functions include multi-Bin card issuance, deposit address generation, cryptocurrency KYT (Know Your Transaction), cardholder KYC (supporting both API integration and hosted mode), and secure, compliant infrastructure. This ensures that the flow of funds remains transparent and controllable throughout the entire process. Additionally, Interlace supports on-chain transfers, multi-account fund allocation, and efficient operations like top-ups, transfers, and card issuance, addressing the needs of a wide range of use cases.

In terms of CaaS, Interlace offers multi-BIN configurations to support clients’ global card issuance requirements. Its advanced risk control and anti-fraud system enable real-time transaction monitoring, safeguarding the security of funds. Interlace also provides a white-label API integration, allowing clients to customize card designs and enabling businesses to rapidly create unique brand differentiation.

Michael also emphasized that stablecoins are playing an increasingly crucial role in cross-border payments. Driven by technological innovation, Interlace provides industry-leading solutions that deliver the infrastructure for secure and efficient fund transfers, empowering institutions and clients to gain a competitive edge in the evolving integration of cryptocurrency with traditional payment systems.

Founded in 2019, Interlace has quickly established itself as a leader in the fintech space, earning the highest security certification in the international card payment industry, PCI-DSS Level 1. The company has also obtained licenses in key regions including the United States, and Lithuania. To date, Interlace has issued over 4.5 million cards and served 7,500 businesses worldwide, processing over 60 million transactions annually.

WABCOWÜRTH RELIES ON GETAC: RELIABLE COMMERCIAL VEHICLE DIAGNOSTICS UNDER TOUGH CONDITIONS

GETAC S410 LAPTOPS IN USE IN COMMERCIAL VEHICLE DIAGNOSTICS THROUGHOUT EUROPE

TAIPEI, Feb. 26, 2025 /PRNewswire/ — WABCOWÜRTH Workshop Services GmbH, a joint venture between the Würth Group and the Commercial Vehicle Control Systems Division of the ZF Group, is using Getac S410 rugged laptops for increased efficiency of its multi-brand diagnostic systems for commercial vehicles across Europe. The powerful Getac rugged laptops were chosen for their high resilience, ease of use and excellent connectivity. They can be easily adapted to a wide range of EU requirements, so that several thousand devices have now been successfully in use since the beginning of 2024: in harsh workshop environments, outdoors, in a wide range of weather conditions and many other challenges.

Getac S410 laptops in use in commercial vehicle diagnostics throughout Europe.
Getac S410 laptops in use in commercial vehicle diagnostics throughout Europe.

WABCOWÜRTH specialises in multi-brand diagnostic solutions for commercial vehicles. Its W.EASY diagnostic systems, consisting of hardware and software, must reliably withstand the tough everyday working conditions in specialised workshops: in hot and cold conditions, during outdoor testing work, in all weathers or when operating with dirty hands. As well as being used on docking stations and bespoke trolley’s, they are also perched and/or rested directly onto a dirty engine bay. 

The robust solution from an other manufacturer that had been used to date no longer quite met the required functionality and flexibility, so WABCOWÜRTH performed extensive analysis procedures to decide on a new supplier. “The overall package of price, performance, value, quality & design and the excellent communication with Getac convinced us,” says Patrick Koch, Product Manager Diagnostic at WABCOWÜRTH.

Efficient maintenance: The advantages of the Getac Self-Maintainer programme

Another advantage is the Getac Self-Maintainer programme: spare parts can be obtained quickly and minor repairs can be carried out quickly and easily. Any device downtimes are reduced to a minimum.

Another decision-making factor was the first-class connectivity: Getac’s S410 communicates stably with the diagnostic interface via WLAN and Bluetooth, even over long distances. This is important for outdoor use. The S410 laptops have proven their value: They are powerful, user-friendly, have consistently easy-to-read displays even in outdoor use, and ensure high reliability – even in very harsh workshop environments or outdoors. “The devices work reliably and perfectly; so far we haven’t had a single complaint. So it couldn’t be better,” explains Patrick Koch. The close cooperation with Getac and its Platinum Partner PWA Electronic, through which WABCOWÜRTH purchases its devices, enables customised solutions at the highest level.

Eric Yeh, Managing Director of Getac Technology GmbH, says: “We are delighted with the successful deployment of our Getac S410 rugged laptops at WABCOWÜRTH – a further evidence of our commitment to not only providing leading rugged computing solutions, but also optimal, customer-centric, intelligent service capabilities.”

As a result, WABCOWÜRTH’s decision in favor of the Getac S410 was groundbreaking in helping to cope with the high demands of tough working conditions in a competitive European market. The S410s are helping the company to increase the efficiency of its diagnostic solutions and guarantee lasting customer satisfaction. WABCOWÜRTH is already planning further projects with Getac and PWA Electronic, possibly including the use of devices with significant technological innovations.

About Getac:

Getac Technology Corporation is a global leader in AI-capable rugged mobile technology and intelligent video solutions, including laptops, tablets, software, body-worn cameras, in-car video systems, digital evidence management and enterprise video analytics solutions. Getac’s solutions and services are designed to enable extraordinary experiences for frontline workers in challenging environments. Today, Getac serves customers in over 100 countries spanning defence, public safety, ambulance, fire & rescue, utilities, automotive, natural resources, manufacturing, transport, and logistics. Getac was recently recognized as one of Newsweek’s “World’s Most Trustworthy Companies” for 2024. For more information, visit: http://www.getac.com. Participate in the Getac Industry blog or follow the company on LinkedIn and YouTube

Getac and Getac logo are trademarks of Getac Holdings Corporation or its affiliates. Other brands or trademarks are the property of their respective owners. ©2025 Getac Technology Corporation.

MBS Pioneers International Live Broadcast with TVU Solutions for Osaka Expo Warm-up

Leading up to Osaka Expo 2025, Japanese Broadcaster Successfully Deploys Innovative Broadcasting Solutions to Deliver Seamless Multi-National Cities Live Coverage

CUPERTINO, Calif., Feb. 25, 2025 /PRNewswire/ — Mainichi Broadcasting System (MBS) has pioneered groundbreaking international live coverage across multiple nations, leveraging TVU Networks’ innovative broadcasting solutions to showcase preparations for the Osaka Expo 2025. Opening April 13, 2025, the Expo will unite more than 150 countries and international organizations under the theme “Designing Future Society for Our Lives,” with projected attendance exceeding 28 million visitors.

In anticipation of this momentous occasion, MBS launched an ambitious broadcast initiative, establishing simultaneous live broadcast capabilities in multinational cities including Dubai and Istanbul through TVU’s advanced technology. The coverage from Dubai, host of the previous World Expo, proved particularly compelling—capturing both the city’s futuristic skyline and technological marvels alongside traditional souks and historic mosques, embodying the Expo’s mission of fostering cultural exchange.

Prior to deployment, MBS conducted rigorous equipment evaluations before selecting TVU’s comprehensive broadcasting solutions, with the TVU One backpack serving as their technical cornerstone, complemented by TVU Anywhere. The TVU One’s proprietary IS+ technology masterfully orchestrates multiple carrier network resources, creating a robust defense against signal disruptions in the field. Enhanced by H.265 intelligent variable bitrate encoding and Forward Error Correction (FEC), the system ensures high-fidelity, low-latency video transmission.

MBS Pioneers International Live Broadcast with TVU Solutions for Osaka Expo Warm-up
MBS Pioneers International Live Broadcast with TVU Solutions for Osaka Expo Warm-up

MBS reporters maximized TVU Anywhere’s mobility advantages, transforming smartphones into professional broadcasting tools for agile urban coverage. The application’s IS+ algorithm created robust transmission channels in high-traffic areas by seamlessly integrating 5G/4G and WiFi signals, ensuring uninterrupted delivery of high-quality live content.

“The synergy between TVU One and TVU Anywhere surpassed our performance expectations,” noted Teruhisa Kusanagi, Technical Production Center at MBS. “The system’s resilience in densely populated areas particularly impressed us. The IS+ technology maintained stable transmission even in demanding environments like the Dubai Mall and Spice Souk, reducing both setup time and costs.”

Rick Asahina, Senior Director of TVU Networks Japan, emphasized: “This pioneering broadcast demonstrates the full potential of our integrated solutions in supporting ambitious, multi-national live productions. MBS’s strategic deployment created a dynamic coverage approach balancing professional broadcast quality with operational flexibility. The successful transmission across major cities validates our commitment to developing resilient broadcast solutions capable of performing in any environment.”

FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review

MELBOURNE, Australia, Feb. 26, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for its breakthrough investigational kidney cancer PET[1] imaging agent TLX250-CDx  (Zircaix®[2], 89Zr-DFO-girentuximab), granted a Priority Review and provided a PDUFA[3] date of 27 August 2025, paving the way for a U.S. commercial launch in 2025.

If approved, TLX250-CDx will become the first commercially available imaging agent to accurately and non-invasively diagnose and characterize clear cell renal cell carcinoma (ccRCC), the most common and one of the most aggressive sub-types of kidney cancer. It works by specifically binding to carbonic anhydrase IX (CAIX), a validated target protein expressed on 95% of ccRCC cells to produce images with high tumor-to-background ratio and high intra- and inter-reader consistency.

The BLA is based on Telix’s successful global Phase 3 ZIRCON[4] study, which demonstrated a sensitivity of 86%, specificity of 87% and a positive predictive value (PPV) of 93% for ccRCC, including in very small, difficult-to-detect lesions[5]. The results of this study were published in The Lancet Oncology in September 2024, in a peer-reviewed manuscript by Professor Brian Shuch (University of California, Los Angeles, UCLA) and colleagues[6]. The paper outlines the critical unmet need for a new, non-invasive technique that can accurately detect and differentiate ccRCC from other renal masses in patients and concluded that TLX250-CDx meets this need and ‘has the potential to be practice changing.’ 

Kevin Richardson, Chief Executive Officer, Precision Medicine, said, “We are delighted that the FDA has accepted this BLA as it moves us one step closer to bringing our breakthrough product to patients. We are aiming to revolutionize the management of kidney cancer, just as PSMA-PET/CT[7] scanning has changed the management of prostate cancer. By providing a more definitive clinical diagnosis for renal masses, we believe that Zircaix[2] will help physicians make more timely and confident patient management decisions and more quickly provide patients with a clear understanding of their disease and treatment options. Building further on Telix’s successful urology franchise, we are preparing to bring this powerful precision medicine product to market in 2025[8].”

About TLX250-CDx

TLX250-CDx (Zircaix®[2]) is an investigational PET agent that is under development for the diagnosis and characterization of ccRCC. Telix’s pivotal Phase 3 ZIRCON trial evaluating TLX250-CDx in 300 patients, of whom 284 were evaluable, met all primary and secondary endpoints, including showing 86% sensitivity and 87% specificity and a 93% PPV for ccRCC across three independent radiology readers[5]. Telix believes this demonstrated the ability of TLX250-CDx to reliably detect the clear cell phenotype and provide an accurate, non-invasive method for diagnosing and characterizing ccRCC. Confidence intervals exceeded expectations amongst all three readers, showing evidence of high accuracy and consistency of interpretation. 

As part of Telix’s commitment to access to medicine, the Company operates an expanded access program (EAP) in the U.S.[9], named patient programs (NPPs) in Europe, and a special access scheme (SAS) in Australia to allow continued access to TLX250-CDx outside of a clinical trial, to patients for whom there are no comparable or satisfactory alternate options. TLX250-CDx has not received a marketing authorization in any jurisdiction and is for investigational use only.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedInX and Facebook.

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

Legal Notices

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

©2025 Telix Pharmaceuticals Limited. Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country.

[1] Positron emission tomography.
[2] Brand name subject to final regulatory approval. 
[3] Prescription Drug User Fee Act.   
[4] Zirconium iRenal Cancer Oncology, ClinicalTrials.gov ID: NCT03849118.
[5] Telix ASX disclosures 7 November 2022.
[6] Shuch et al. Lancet Oncology. 2024.
[7] Imaging of prostate-specific membrane antigen with positron emission tomography/computed tomography.
[8] Subject to regulatory approval.
[9] ClinicalTrials.gov ID: NCT06090331.

HBM Alpha Therapeutics Enters Strategic Collaboration and License Agreement to Advance Novel Endocrine Therapies

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , Feb. 26, 2025 /PRNewswire/ — HBM Alpha Therapeutics (HBMAT), Inc., an innovative biotechnology company incubated by Harbour BioMed (HKEX: 02142), announced a strategic collaboration and license agreement with a business partner to advance novel therapies targeting corticotropin-releasing hormone (CRH) for various disorders.

Under the agreement, the partner gains exclusive global rights, excluding Greater China (mainland China, Taiwan, Hong Kong, and Macau), to develop and commercialize HAT001 (designated as HBM9013 by Harbour BioMed), a potent and selective anti-CRH-neutralizing antibody. In return, HBMAT is eligible to receive up to $395 million, including upfront, development, regulatory and commercial milestone payments, as well as tiered royalties on future net product sales. Additionally, HBMAT is also entitled to a warrant to receive minority interest in the partner.

HAT001/HBM9013 is designed to neutralize CRH for various disorders, including congenital adrenal hyperplasia (CAH). CAH is a group of autosomal recessive diseases due to mutations in genes that encode for enzymes necessary for synthesis of key adrenal hormones, which lead to serious health consequences. Current standard of care therapy of CAH was introduced more than 70 years ago. It has not changed significantly since and still has huge unmet medical needs. HAT001/HBM9013 aims to dramatically improve standard of care and improve patient outcomes. It has demonstrated strong preclinical efficacy in downregulating CRH-mediated induction of adrenocorticotropic hormone (ACTH) and is being advanced toward clinical development.

“This collaboration represents a pivotal step for HBMAT in our mission to deliver innovative solutions for patients facing challenging endocrine disorders. The completion of this transaction also marks Harbour BioMed’s partial exit from the first global NewCo we incubated,” said Dr. Jingsong Wang, Founder, Chairman & CEO of Harbour BioMed, and Chairman of BOD of HBMAT. “HAT001/HBM9013 has the potential to be a transformative therapy. With their expertise in drug development, our partner is well-positioned to help bring this therapy to patients worldwide.”

About HBM Alpha Therapeutics

HBM Alpha Therapeutics is a company presently developing antibody therapeutics aimed at the rare genetic disease congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS). Its therapeutics could also be indicated for other endocrinological diseases related to the dysregulation and function of the hypothalamus-pituitary-adrenal (HPA) axis.

HBMAT was founded and incorporated in Delaware, USA in 2019. It is a joint venture between Harbour BioMed and Boston Children’s Hospital, an affiliate of Harvard Medical School. For more information, please visit www.hbmalphatx.com.

About Harbour BioMed

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on immunology and oncology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners, and select acquisitions.
 
The proprietary antibody technology platforms Harbour Mice® generates fully human monoclonal antibodies in two heavy and two light chains (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology is capable of delivering tumor-killing effects unachievable by traditional combination therapies. Integrating Harbour Mice®, and HBICE® with a single B cell cloning platform, our antibody discovery engine is highly unique and efficient for the development of next-generation therapeutic antibodies. For further information, please refer to www.harbourbiomed.com.

Tenchijin Selected as Data Service Provider of Japan Space Agency’s Advanced Land Observing Satellite-4 (ALOS-4)

TOKYO, JAPAN – Media OutReach Newswire – 26 February 2025 – Tenchijin, Inc. (Chuo-ku, Tokyo, CEO: Yasuhito Sakuraba), a Japanese satellite tech company endorsed by the Japan Aerospace Exploration Agency JAXA, has been selected as a data service provider to utilize the PALSAR-3 observation data of Advanced Land Observing Satellite-4 “DAICHI-4”(ALOS-4), which is carried out by Space Technology Directorate I of JAXA. Tenchijin will provide data services to the general public using ALOS-4 observation data until March 2028.

Tenchijin Selected as Data Service Provider of Japan Space Agency's Advanced Land Observing Satellite-4 (ALOS-4)
Tenchijin Selected as Data Service Provider of Japan Space Agency’s Advanced Land Observing Satellite-4 (ALOS-4)

This will be the first online sale¹ of such data in Japan and will enable anyone to easily and immediately purchase the data of their interest in a small area at a low price. The timing of the service will be announced shortly.

¹Users can select data, place orders, and make payments all online.

About Advanced Land Observing Satellite-4 “DAICHI-4”(ALOS-4)

The Advanced Land Observing Satellite-4 (ALOS-4) is a satellite that observes Earth’s surface using its onboard phased array type L-band synthetic aperture radar (PALSAR-3). The L-band radar technology has continuously been developed in Japan. With further improved observation performance compared to the predecessor PALSAR-2 aboard the DAICHI-2 (ALOS-2), JAXA and its prime contractor, Mitsubishi Electric Corporation, are developing the satellite, aiming to achieve both high resolution and a broader observation swath.
Unlike observations by an optical sensor, radar images can be acquired day and night, as it does not require sunlight. Moreover, since radio waves can penetrate clouds, the images can be obtained regardless of weather conditions. The ALOS-4 will leverage these merits for observing and monitoring disaster-hit areas, forests, and sea ice. In addition, it will also challenge new areas, such as monitoring infrastructure displacement.

Reference: https://global.jaxa.jp/projects/sat/alos4/

About the Public Solicitation for Data Service Provider Using Observation Data of ALOS-4

JAXA aims to provide data and services to the general public, mainly through the private sector, as part of its efforts to expand the ALOS-4 observation data and service business through public-private partnerships.

This time, as part of the public solicitation for the selection of the private-sector operator, JAXA requested proposals for a project to provide ALOS-4 data to general users until FY2027. Proposals were requested to include an outline of the project, including a mechanism for general users to access ALOS-4 observation data, a project concept and vision, a schedule and implementation structure, and other information such as the price for providing data services.

Reference: https://www.satnavi.jaxa.jp/ja/news/2024/07/30/9597/index.html

Tenchijin’s Thoughts on the Space Industry

Tenchijin has launched a new initiative to expand the use of satellite data in Japan. Satellite data has the power to solve social issues in a wide range of fields, including agriculture, disaster prevention, urban planning, and energy. However, in Japan, issues such as technical hurdles, cost, and lack of awareness have hindered the spread of data. The goal of Tenchijin is to change this situation and transform satellite data from something special to something familiar.

ALOS-4, launched by JAXA in 2024, will play an innovative role in the fields of crustal deformation, disaster prevention, forest management, and agriculture with the world’s highest resolution and observation coverage. For example, in disaster-prone Japan, the ability to observe at night and under bad weather conditions can be utilized to quickly assess damage from heavy rainfall and earthquake disasters. In addition, the system is expected to be used in a variety of ways toward a sustainable society, such as estimating forest carbon stocks and determining crop acreage in the agricultural sector.

Tenchijin will make the data provided by ALOS-4 available to as many people as possible. First, Tenchijin will provide an intuitive platform that is easy for anyone to use, enabling data analysis without special knowledge. In addition, Tenchijin will develop a service model with low introduction costs to create an environment in which small and medium-sized companies and local governments can easily utilize the service. Furthermore, Tenchijin will proactively disseminate best practices and work to ensure that the value of satellite data is widely recognized.

In addition, Tenchijin will focus on human resource development through training and workshops to broaden the base of professionals who can handle data. Tenchijin will also work with local governments, private companies, and educational institutions to build an ecosystem that can solve social issues from a variety of perspectives.

The power of data will change the future. Based on this belief, Tenchijin will do its utmost to realize a sustainable future by maximizing the power of satellite data.

About Tenchijin COMPASS

In July 2022, Tenchijin released a free plan for its land evaluation engine, Tenchijin COMPASS. Tenchijin COMPASS is a land evaluation service that comprehensively analyzes, visualizes, and provides data based on various data, including big data from earth observation satellites. It can be customized for various purposes, from agricultural production to urban development, and it can find the best land for business from space.

Many people think of satellite data as photos taken from satellites. Images taken from satellites are typical satellite data, but Tenchijin COMPASS can also obtain weather information such as precipitation, topographical information represented by 3D maps, and surface temperatures observed by infrared light anywhere in the world.

Tenchijin COMPASS also allows to overlay ground data and performance data that are already available to perform composite analysis.

How to use Tenchijin COMPASS

・Cost: free
・Supported languages: English, Japanese
・Supported browsers: Google Chrome recommended, PC only
・Website URL: https://tenchijin.co.jp/compass/
Contact: info-compass@tenchijin.co.jp

Hashtag: #Tenchijin #Space #SatelliteTechnology #Sustainability




The issuer is solely responsible for the content of this announcement.

Tenchijin, Inc.

E-Mail: (person in charge of communication: Keisuke Sunagare)
Address: THE EAST Nihonbashi 1-chome ROOM13, 5th floor, Mitsui Building, 1-4-1 Nihonbashi, Chuo-ku, Tokyo
Representative: Yasuhito Sakuraba, CEO
Business content: land evaluation consulting using satellite data
Business activities: land valuation consultancy, service development and operation using satellite data

Main clients
Water: Tokyo city, Aomori city, Fukushima city
Agriculture: Shinmei Corporation, Seiwa Corporation
Telecommunication: Nippon Telegraph and Telephone East Corporation

Tenchijin welcomes any inquiries from companies in the water-related business sector. (contact email: , person in charge: Keitaro Asaba)

Everest Medicines Presents Complete Maintenance Period Data for Etrasimod at ECCO 2025

  • Data confirms significant clinical and endoscopic benefits of etrasimod 2mg after 40 weeks of maintenance treatment
  • Etrasimod demonstrates robust efficacy across multiple endpoints, including mucosal healing, endoscopic normalization, and histological remission
  • Safety profile remains consistent with previous studies, with no new safety findings were observed

SHANGHAI, Feb. 26, 2025 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the presentation of maintenance data from its multi-center Phase III clinical study of etrasimod (VELSIPITY®) in Asia at the 20th European Crohn’s and Colitis Organization Congress (ECCO 2025).

Etrasimod, a next-generation, once-daily selective sphingosine-1-phosphate (S1P) receptor modulator, is being developed for the treatment of moderately to severely active ulcerative colitis (UC). To date, etrasimod is the only advanced UC therapy that has completed a large-scale, randomized, controlled pivotal study in the Asia-Pacific region. The findings of the ES101002 study provide robust evidence supporting the use of etrasimod in UC patients.

The positive results come from a multicenter, randomized, double-blind, placebo-controlled Phase 3 study of etrasimod conducted in the Asian region. This is the largest pivotal Phase 3 study to date in Asian population with moderately to severely active ulcerative colitis. A total of 340 eligible patients with an inadequate response to, loss of response to, or intolerance to at least 1 prior UC treatment were randomized in a 2:1 ratio to receive either etrasimod 2mg once daily or placebo for 12 weeks in the induction period. All patients who completed the induction treatment and were responders at week 12 entered a 40-week maintenance period in which patients were re-randomized in a 1:1 ratio to receive etrasimod 2mg once-daily or placebo for up to 40 weeks.

The results demonstrate that treatment with etrasimod 2 mg resulted in a clinically meaningful and statistically significant improvement in the primary and all secondary endpoints at the end of maintenance period. A statistically significant greater proportion of etrasimod-treated patients achieved clinical remission at Week 40 compared with placebo (etrasimod: 48.1%; placebo: 12.5%; difference = 35.9%; 95% CI: [22.5%, 49.2%]; 2-sided p value < 0.0001).  A statistically significant greater proportion of etrasimod-treated patients achieved endoscopic improvement (etrasimod: 61.0%; placebo: 15.0%, difference = 46.6% [95% CI : 33.2%,60.1%], 2-sided p value < 0.0001) and clinical response (etrasimod: 79.2%; placebo: 35.0%, difference = 45.6% [ 95% CI :31.9%,59.3%], 2-sided p value < 0.0001) at week 40 compared with placebo. Other secondary endpoints of mucosal healing, endoscopic normalization, and histological remission also significantly favored patients treated with etrasimod compared with placebo. Notably, mucosal healing as measured by a central read endoscopic subscore≤ 1 (excluding friability) with a Geboes Index score < 2.0, was achieved in 51.9% of the etrasimod treated patients compared to 8.8% in the placebo group (2-sided p-value <0.0001). The safety profile of etrasimod during the maintenance period was consistent with previous studies, with no new safety findings observed.

“The positive results of etrasimod’s maintenance data presented at one of the world’s leading academic conferences on inflammatory bowel disease further confirms its advantages as an innovative therapy for UC,” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “Autoimmune diseases have always been a key research focus for Everest. We are committed to enhancing the accessibility and clinical application of etrasimod, and moving forward, we aim to expand its availability across Asia to benefit more appropriate patients.”

“As the only drug that has been proven to be effective in UC patients with moderately to severely active isolated proctitis in the global Phase III ELEVATE clinical trials, in the results of the Asian multi-center Phase 3 clinical trial of etrasimod for the treatment of moderately to severely active UC, etrasimod achieved positive topline data results in both the induction and maintenance treatment periods.” said Prof. Wu Kaichun at the First Affiliated Hospital of AFMU who is the principal investigator for etrasimod’s Asia clinical trial.“As a next-generation selective S1P receptor modulator, once-daily oral etrasimod has a rapid onset of action, significantly increases the proportion of patients with clinical remission,endoscopic normalization and mucosal healing, and helps patients to reach their treatment goals sooner. We look forward to more patients with ulcerative colitis benefiting from etrasimod in the future.”

As a core product of Everest Medicines, etrasimod is an innovative and advanced therapy that provides rapid onset of action, clinical remission and mucosal healing through an oral, once-daily regimen. Etrasimod has been commercially launched in Macau in 2024. The new drug application has also been officially accepted in mainland China and Hong Kong, and etrasimod has officially been approved for adult patients with moderately to severely active UC by the Guangdong Provincial Medical Products Administration and can be used in the medical institutions designated by the Connect Policy in the Greater Bay Area, The first prescription in mainland Guangdong, Foshan, has been issued for the drug in the Greater Bay Area.

About VELSIPITY® (etrasimod)

VELSIPITY® is a once-daily, oral, sphingosine 1-phosphate (S1P) receptor modulator that selectively binds with S1P receptor subtypes 1, 4, and 5. Regulatory approvals have been granted in US, EU, Canada, Australia, Singapore, UK, Switzerland, Israel and Macau, China for VELSIPITY® in ulcerative colitis.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com

Forward-Looking Statements:

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

STAK Inc. Announces Pricing of Initial Public Offering

CHANGZHOU, China, Feb. 26, 2025 /PRNewswire/ — STAK Inc. (the “Company” or “STAK”), a fast-growing company specializing in the research, development, manufacturing, and sale of oilfield-specialized production and maintenance equipment, today announced the pricing of its initial public offering (the “Offering”) of 1,250,000 ordinary shares at a public offering price of US$4.00 per ordinary share. The ordinary shares have been approved for listing on the Nasdaq Capital Market and are expected to commence trading on February 26, 2025, under the ticker symbol “STAK.” The Offering is expected to close on or about February 27, 2025, subject to the satisfaction of customary closing conditions.

The Company expects to receive aggregate gross proceeds of US$5 million from the Offering, before deducting underwriting discounts and other related expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 187,500 ordinary shares, representing 15% of the ordinary shares sold in the Offering, at the public offering price less underwriting discounts.

The Offering is being conducted on a firm commitment basis. Kingswood Capital Partners, LLC is acting as the representative of the underwriter.

A registration statement on Form F-1 relating to the Offering was filed with the Securities and Exchange Commission (the “SEC”) (File Number: 333-283258), as amended, and was declared effective by the SEC on February 25, 2025. The Offering is being made only by means of a prospectus forming a part of the registration statement. Copies of the prospectus relating to the Offering may be obtained, when available, from Kingswood Capital Partners, LLC at 7280 W Palmetto Park Rd., Suite 301, Boca Raton, FL 33433, or via email at bherman@kingswoodus.com, or telephone at (561) 961-0505. In addition, copies of the prospectus relating to the Offering may be obtained via the SEC’s website at www.sec.gov.

Before you invest, you should read the registration statement and the preliminary prospectus contained therein and the final prospectus, when available, and other documents the Company has filed or will file with the SEC for more complete information about the Company and the Offering. This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company’s securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company’s securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About STAK Inc.

STAK Inc. is a fast-growing company specializing in the research, development, manufacturing, and sale of oilfield-specific production and maintenance equipment. The Company designs and manufactures oilfield-specialized production and maintenance equipment, then collaborates with qualified specialized vehicle manufacturing companies to integrate the equipment onto vehicle chassis, producing specialized oilfield vehicles for sale. Additionally, the Company sells oilfield-specialized equipment components, related products, and provides automation solutions. Its vision is to help oilfield services companies reduce costs and increase efficiency by providing the cutting-edge integrated oilfield equipment and automation solutions service. Its mission is to become a powerful provider for the niche markets of specialized oilfield vehicles and equipment in China. For more information, please visit the Company’s website at https://www.stakindustry.com/ir/.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, including, but not limited to, the Company’s proposed Offering. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs, including the expectation that the Offering will be successfully completed. Investors can find many (but not all) of these statements by the use of words such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “potential,” “intend,” “plan,” “believe,” “likely to” or other similar expressions in this prospectus. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC.

For more information, please contact:

STAK Inc.
Investor Relations Department
Email: ir@stakindustry.com

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com